Page 67 - e-CPG-SLE-8_5_24

Management of Systemic Lupus Erythematosus

74. Morand EF, Furie R, Tanaka Y, et al. Trial of Anifrolumab in Active Systemic
Lupus Erythematosus. N Engl J Med. 2020;382(3):211-221.
75. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in
moderately-to-severely active systemic lupus erythematosus: the randomized,
double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab
trial. Arthritis Rheum. 2010;62(1):222-233.
76. Cobo-Ibanez T, Loza-Santamaria E, Pego-Reigosa JM, et al. Efficacy and
safety of rituximab in the treatment of non-renal systemic lupus erythematosus:
a systematic review. Semin Arthritis Rheum. 2014;44(2):175-185.
77. Li QY, Yu F, Zhou FD, et al. Plasmapheresis Is Associated With Better Renal
Outcomes in Lupus Nephritis Patients With Thrombotic Microangiopathy: A
Case Series Study. Medicine (Baltimore). 2016;95(18):e3595.
78. Soyuoz A, Karadag O, Karaagac T, et al. Therapeutic plasma exchange for
refractory SLE: A comparison of outcomes between different sub-phenotypes.
Eur J Rheumatol. 2018;5(1):32-36.
79. Monova D, Monov S. Treatment of active lupus nephritis: intravenous
immunoglobulin G versus cyclophosphamide or azathioprine. BANTAO J.
2006;4(2):13.
80. Mulhearn B, Bruce IN. Indications for IVIG in rheumatic diseases. Rheumatology
(Oxford). 2015;54(3):383-391.
81. Guo Y, Tian X, Wang X, et al. Adverse Effects of Immunoglobulin Therapy. Front
Immunol. 2018;9:1299.
82. Weening JJ, D’Agati VD, Schwartz MM, et al. The classification of
glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int.
2004;65(2):521-530.
83. Ministry of Health Malaysia. Management of Chronic Kidney Disease. 2nd ed.
Putrajaya: MOH 2018.
84. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients
with active proliferative lupus nephritis: the Lupus Nephritis Assessment with
Rituximab study. Arthritis Rheum. 2012;64(4):1215-1226.
85. Furie R, Rovin BH, Houssiau F, et al. Two-Year, Randomized, Controlled Trial of
Belimumab in Lupus Nephritis. N Engl J Med. 2020;383(12):1117-1128.
86. Hannon CW, McCourt C, Lima HC, et al. Interventions for cutaneous
disease in systemic lupus erythematosus. Cochrane Database Syst Rev.
2021;3(3):CD007478.
87. Thomas G, Cohen Aubart F, Chiche L, et al. Lupus Myocarditis: Initial
Presentation and Longterm Outcomes in a Multicentric Series of 29 Patients. J
Rheumatol. 2017;44(1):24-32.
88. Mosca M, Tani C, Aringer M, et al. European League Against Rheumatism
recommendations for monitoring patients with systemic lupus erythematosus in
clinical practice and in observational studies. Ann Rheum Dis. 2010;69(7):1269-
1274.
89. Bertsias G, Ioannidis JP, Boletis J, et al. EULAR recommendations for the
management of systemic lupus erythematosus. Report of a Task Force of
the EULAR Standing Committee for International Clinical Studies Including
Therapeutics. Ann Rheum Dis. 2008;67(2):195-205.
90. Chen D, Xie J, Chen H, et al. Infection in Southern Chinese Patients with
Systemic Lupus Erythematosus: Spectrum, Drug Resistance, Outcomes, and
Risk Factors. J Rheumatol. 2016;43(9):1650-1656.
91. Wu Q, Liu Y, Wang W, et al. Incidence and prevalence of tuberculosis in
systemic lupus erythematosus patients: A systematic review and meta-analysis.
Front Immunol. 2022;13:938406.

50